{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["175(2)"],"submitter":["Jensen LR"],"funding":["National Hospital"],"pubmed_abstract":["Background
Treatment-refractory meningioma is a widely used term but lacks standardized criteria, impairing research comparability and treatment evaluation. The aim of this study was to assess the heterogeneity of patient populations labeled as treatment-refractory and to explore recommendations for better consistency.Methods
We systematically reviewed 69 studies published before 2024 and analyzed individual participant data from 15 cohorts (n = 211) that included treatment-refractory patients who underwent experimental therapy with somatostatin receptor (SSTR)-targeted therapies. A reference cohort (n = 102) with newly diagnosed WHO-3 meningiomas was used descriptively for comparison. Progression and death were the primary endpoints. Hazard rate ratios were estimated via P"],"journal":["Journal of neuro-oncology"],"pagination":["599-610"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12420741"],"repository":["biostudies-literature"],"pubmed_title":["The concept, intention, and evaluation of the term treatment-refractory meningioma."],"pmcid":["PMC12420741"],"pubmed_authors":["Ruiz-Patino A","Maier AD","Meling TR","Brokinkel B","Rodriguez AO","Juratli TA","Graillon T","Clement PM","Torp SH","Cardona AF","Bota DA","Ruda R","Walter MA","Gupta T","Furtner J","van Essen M","Suh CO","Munch TN","Mirian C","Goutagny S","Arrieta O","Gousias K","Kristensen BW","Mathiesen T","Hrachova M","Scheie D","Bertero L","Preusser M","Chang JH","Tabernero MD","Jensen LR","Law I","Fugleholm K"],"additional_accession":[]},"is_claimable":false,"name":"The concept, intention, and evaluation of the term treatment-refractory meningioma.","description":"Background
Treatment-refractory meningioma is a widely used term but lacks standardized criteria, impairing research comparability and treatment evaluation. The aim of this study was to assess the heterogeneity of patient populations labeled as treatment-refractory and to explore recommendations for better consistency.Methods
We systematically reviewed 69 studies published before 2024 and analyzed individual participant data from 15 cohorts (n = 211) that included treatment-refractory patients who underwent experimental therapy with somatostatin receptor (SSTR)-targeted therapies. A reference cohort (n = 102) with newly diagnosed WHO-3 meningiomas was used descriptively for comparison. Progression and death were the primary endpoints. Hazard rate ratios were estimated via P","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-03T05:47:29.476Z","creation":"2026-04-25T03:14:51.898Z"},"accession":"S-EPMC12420741","cross_references":{"pubmed":["40760312"],"doi":["10.1007/s11060-025-05154-2"]}}